An individual’s genetic blueprint holds vital information that can be used to improve their clinical management should they ever get cancer, and to provide better information and risk-reducing strategies for their relatives. However, current availability of genetic testing remains very restricted, even though new testing methods can potentially be used quickly, affordably and on a large-scale.
The SMC invited four experts from genetics and oncology to brief journalists on the challenges and opportunities of bringing genetic testing into routine cancer care. They answered questions such as:
Professor Nazneen Rahman, Head of Division of Genetics and Epidemiology, The Institute of Cancer Research, London, & Head of the Cancer Genetics Clinical Unit, Royal Marsden NHS Foundation Trust
Professor Peter Donnelly, Director, Wellcome Trust Centre for Human Genetics (WTCHG), Professor of Statistical Science, University of Oxford
Professor Martin Gore, Medical Director, Royal Marsden NHS Foundation Trust, Professor of Cancer Medicine, The Institute of Cancer Research, London
Dr Clare Turnbull, Team Leader in Division of Genetics, The Institute of Cancer Research, London, & Consultant in Clinical Genetics, Royal Marsden Hospital NHS Foundation Trust